Close Menu

NEW YORK (GenomeWeb) – Cancer diagnostics firm Oncimmune said today that it has acquired Protagen Diagnostics for up to £4.1 million ($5.5 million).

The final price is subject to performance milestones and will be paid in Oncimmune shares issued at 156p ($2.07) per share, which it said was a premium of 71 percent over its closing price on March 18, 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.